Fourth, our results may not apply to all patients since SGLT2 inhibitors and GLP-1 RAs are increasingly being used as front-line agents in T2D, while our cohort entry criteria required prior use of metformin. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.